Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Liabilities (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Total Liabilities data on record, last reported at $29.4 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 0.79% year-over-year to $29.4 million; the TTM value through Sep 2025 reached $29.4 million, up 0.79%, while the annual FY2024 figure was $30.2 million, 40.62% down from the prior year.
  • Total Liabilities reached $29.4 million in Q3 2025 per PLX's latest filing, up from $28.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $104.4 million in Q2 2021 and bottomed at $28.6 million in Q2 2025.
  • Average Total Liabilities over 5 years is $59.0 million, with a median of $63.0 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: grew 27.41% in 2024, then crashed 54.6% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $79.7 million in 2021, then fell by 16.65% to $66.4 million in 2022, then fell by 23.43% to $50.9 million in 2023, then plummeted by 40.62% to $30.2 million in 2024, then dropped by 2.81% to $29.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $29.4 million in Q3 2025, $28.6 million in Q2 2025, and $28.7 million in Q1 2025.